CNBC's Eamon Javers reports on news regarding the White House.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Eli Lilly and Company (NYSE:LLY ) Bernstein 2nd Annual Global Healthcare Conference September 25, 2025 8:00 AM EDT Company Participants Lucas Montarce - Executive VP & CFO Mike Czapar - Director of Investor Relations Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.
Eli Lilly Chief Executive Dave Ricks said Britain was "probably the worst country in Europe" for drug prices in an interview with the Financial Times, intensifying pressure on the government to improve market conditions for drugmakers.
The planned site, which will be used to manufacture the company's first oral weight-loss drug, is expected to be operational within five years.
Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.
Eli Lilly's Mounjaro helped children and adolescents aged 10 to 17 years with type 2 diabetes manage their blood sugar better and lose weight, according to trial results presented at a medical meeting on Wednesday.
Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.
Eli Lilly (LLY) concluded the recent trading session at $763.57, signifying a +2.06% move from its prior day's close.
Lilly CEO Dave Ricks explains why pricing dynamics in the U.K. make it a very unattractive place for Lilly to invest.
Eli Lilly on Tuesday said it will spend $5 billion to build a manufacturing facility in Goochland County, Virginia, to boost production capacity for targeted cancer drugs and other treatments. The plant is the company's first of four planned U.S. manufacturing sites, which will begin making medicines within five years.
Resort-style clothing maker Oxford Industries Inc. on Wednesday offered up mixed second-quarter results and third-quarter expectations, and said that while new Lilly Pulitzer offerings were attracting shoppers, its Tommy Bahama line wasn't.